Related Experiment Video
Updated: Jun 19, 2026
06:31
Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
Published on: October 3, 2019
Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment.
José Manuel Carrascosa Carrillo1, Eulalia Baselga Torres2, Yolanda Gilaberte Calzada3
1Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916, Barcelona, Spain.
Dermatology and Therapy
|April 21, 2022
Summary
Physicians prioritize clinical efficacy and safety when selecting systemic treatments for moderate-to-severe atopic dermatitis (AD). They accept some adverse events for better symptom relief and long-term benefits, guiding optimal therapy choices.
Area of Science:
- Dermatology
- Pharmacology
- Clinical Research
Background:
- Emerging treatments for moderate-to-severe atopic dermatitis (AD) necessitate understanding physician preferences.
- Identifying factors influencing treatment selection is crucial for optimizing patient care.
Purpose of the Study:
- To explore physician preferences for systemic treatments in moderate-to-severe AD.
- To identify sociodemographic factors influencing these preferences.
- To evaluate physician satisfaction with current AD therapies.
Main Methods:
- A discrete-choice experiment (DCE) survey was conducted with physicians treating AD in Spain.
- Conditional logit modeling was used to analyze attribute importance and risk tolerance.
Main Results:
- Clinical efficacy and risk of severe adverse events (AEs) were paramount.
- Improvements in sleep and pruritus, and rapid onset of action were highly valued.
- Physicians accepted increased risk of AEs for enhanced efficacy and long-term benefits.
Conclusions:
- Findings aid prescribers in selecting optimal systemic therapies for moderate-to-severe AD.
- Understanding physician priorities can guide the development and positioning of new AD treatments.
